{
  "docId": "019de072-65f6-7273-bf5f-9dfce8e99600",
  "docSlug": "b41af86b98765dd2459355c3b31d267e",
  "documentTitle": "OmniAb | SPAC Presentation Deck | 35 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 35,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 25,
  "notes": "The chart uses a horizontal bar representation to show the progress of each drug candidate across clinical phases.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-65f6-7273-bf5f-9dfce8e99600/24",
  "deckHref": "/decks/019de072-65f6-7273-bf5f-9dfce8e99600",
  "deckJsonHref": "/decks/019de072-65f6-7273-bf5f-9dfce8e99600.json",
  "deckAnchorHref": "/decks/019de072-65f6-7273-bf5f-9dfce8e99600#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.51,
        "x": 0.45,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Pipeline progress bars",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "913cafaa-9b9b-4e68-bca0-93efe36a4c32",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.92,
        "x": 0.04,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "Animal launch year: OmniRat 2012; OmniMouse 2014; OmniFlic 2014; OmniChicken 2016; OmniClic 2019; OmniTaur 2020. Notes: Most advanced status for each program shown. Zimberelimab and Sugemalimab are approved in China. * Indicates programs with fully paid licenses. † Programs discovered by Teneobio under a fully paid licenses. Future programs discovered under license agreement are subject to downstream economics.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6af52b9f-e0c3-43d3-a1c7-a65c142214b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.64,
        "w": 0.92,
        "x": 0.04,
        "y": 0.19
      },
      "kind": "table",
      "text": "Partner, Program, Source Animal, Area, Target, Preclinical, Phase 1, Phase 2, Phase 3, Registration, Approved",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2e211df-6c7e-476b-a7a6-9d6cda81331a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.92,
        "x": 0.04,
        "y": 0.13
      },
      "kind": "title",
      "text": "TWO APPROVED PRODUCTS AND 23 CLINICAL OMNIAB-DERIVED ANTIBODIES",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22bd0320-74f6-4888-9999-a800a8a0372a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "OMNIAB CLINICAL AND APPROVED PARTNER PIPELINE",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7193705-bfd1-47a8-ae91-51b674ab7d82",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "466e15e0-2112-4ee2-a4b1-5a8bbbbbf06e",
      "evidence": "table/data: Partner, Program, Source Animal, Area, Target, Preclinical, Phase 1, Phase 2, Phase 3, Registration, Approved",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "6988e899-3d8e-4fbe-96a4-0a63d58978cd",
      "evidence": "The table uses horizontal bars to represent the duration and status of clinical trials across phases.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 31,
      "from": 20,
      "beatId": "d8144652-41b6-420d-994f-671137ba6377",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Business Model",
      "beatSlug": "sequoia-pitch-business-model",
      "evidence": "The document presents the business model on pages 20-31",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 24,
      "from": 24,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1c65ff7d-213d-4090-b75e-3ea11eafed15",
      "evidence": "The document presents approved products on page 24",
      "position": 1,
      "objective": "Highlighting the value of approved products",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}